Influence of different chromosomal abnormalities in Ph-positive bone marrow cells on the chronic myeloid leukemia course during tyrosine kinase inhibitors therapy

O. Yu. Vinogradova; Виноградова О. Ю.; E. A. Aseeva; Асеева Е. А.; A. V. Vorontsova; Воронцова А. В.; A. G. Turkina; Туркина А. Г.; A. L. Neverova; Неверова А. Л.; O. V. Lazareva; Лазарева О. В.; E. Yu. Chelysheva; Челышева Е. Ю.; G. A. Gusarova; Гусарова Г. А.; T. I. Kolosheinova; Колошейнова Т. И.; L. Yu. Kolosova; Колосова Л. Ю.; S. R. Goryacheva; Горячева С. Р.; M. V. Vakhrusheva; Вахрушева М. В.; S. M. Kulikov; Куликов С. М.; I. A. Tishchenko; Тищенко И. А.; L. V. Dyachenko; Дяченко Л. В.; A. I. Udovichenko; Удовиченко А. И.; G. A. Alimova; Алимова Г. А.; E. V. Kleina; Клеина Е. В.; L. A. Grebenyuk; Гребенюк Л. А.; M. L. Konnova; Коннова М. Л.; S. Yu. Smirnova; Смирнова С. Ю.; N. D. Khoroshko; Хорошко Н. Д.; E. V. Domracheva; Домрачева Е. В.

doi:10.17650/1818-8346-2012-7-4-24-34

Influence of different chromosomal abnormalities in Ph-positive bone marrow cells on the chronic myeloid leukemia course during tyrosine kinase inhibitors therapy

Authors: Vinogradova O.Y.¹, Aseeva E.A.¹, Vorontsova A.V.¹, Turkina A.G.¹, Neverova A.L.¹, Lazareva O.V.¹, Chelysheva E.Y.¹, Gusarova G.A.¹, Kolosheinova T.I.¹, Kolosova L.Y.¹, Goryacheva S.R.¹, Vakhrusheva M.V.¹, Kulikov S.M.¹, Tishchenko I.A.¹, Dyachenko L.V.¹, Udovichenko A.I.¹, Alimova G.A.¹, Kleina E.V.¹, Grebenyuk L.A.¹, Konnova M.L.¹, Smirnova S.Y.¹, Khoroshko N.D.¹, Domracheva E.V.¹
Affiliations:
1. Hematological Research Center, Ministry of Health of Russia
Issue: Vol 7, No 4 (2012)
Pages: 24-34
Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
Published: 23.11.2012
URL: https://oncohematology.abvpress.ru/ongm/article/view/73
DOI: https://doi.org/10.17650/1818-8346-2012-7-4-24-34
ID: 73

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

The additional molecular and chromosomal abnormalities (ACA) in Phositive cells usually considered as a genetic marker of chronic myeloid leukemia (CML) progression. 457 patients in different CML phases received tyrosine kinase inhibitors (1st and 2nd generation) were studied. During therapy 50 cases with additional chromosomal abnormalities in Ph+ clone (22 of them in chronic CML phase) were revealed (median follow-up from CML diagnosis – 117 months, median imatinib therapy – 62 months). 86 % of patients in chronic phase with Ph+- cell abnormalities were cytogenetic resistance, and their 5-years overall survival was 80 % which was significantly lower than in patients without ACA (p < 0.005). The treatment results depend on chromosomal abnormalities detected. In patients with additional chromosome 8 imatinib therapy is effective, although complete cytogenetic response (CCR) is achieved only in the later therapy stages. In patients with additional translocations CCR also achieved with imatinib or 2nd generation TKI. Only a third of patients with additional Ph-chromosome or BCR/ABL amplification achieved complete suppression of Ph+ clone using 2nd generation TKI. The presence of additional chromosome 7 abnormalities and complex karyotype disorders involving isochromosome i(17)(q10) are poor prognostic factors of TKI treatment failures.

Keywords

chronic myeloid leukemia, additional chromosomal abnormalities, Ph+-cells

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Influence of different chromosomal abnormalities in Ph-positive bone marrow cells on the chronic myeloid leukemia course during tyrosine kinase inhibitors therapy

Full Text

Abstract

Keywords

About the authors

References

Supplementary files